Sugi Predict

Sugi Predict / Compounds / SCHEMBL2377946

SCHEMBL2377946

SCHEMBL2377946

CC1(C#N)CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ VNN1 O95497 1/20 0.46
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CTSK P43235 1/20 0.42
▸ CYP11B2 P19099 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ USP30 Q70CQ3 1/20 0.38
▸ SCD5 Q86SK9 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ NR1H2 P55055 1/20 0.36
▸ GPR183 P32249 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28587335 1.00 VNN1 (0.46) VNN1USP2SMN1; SMN2CTSKCYP11B2
SCHEMBL28604412 1.00 VNN1 (0.46) VNN1USP2SMN1; SMN2CTSKCYP11B2
SCHEMBL22078891 0.91 MEN1 (0.44) VNN1USP2SMN1; SMN2CTSKCYP11B2
SCHEMBL1118226 0.90 USP2 (0.49) VNN1USP2SMN1; SMN2CTSKMEN1
SCHEMBL1706650 0.87 USP2 (0.43) VNN1USP2SMN1; SMN2CTSKMEN1
SCHEMBL22088545 0.84 USP2 (0.42) USP2SMN1; SMN2CTSKCYP11B2MEN1
SCHEMBL22983897 0.84 USP2 (0.42) USP2SMN1; SMN2CTSKCYP11B2MEN1
SCHEMBL22983705 0.84 USP2 (0.42) USP2SMN1; SMN2CTSKCYP11B2MEN1
SCHEMBL30922631 0.81 USP2 (0.55) USP2SMN1; SMN2CTSKCYP11B2MEN1
SCHEMBL2378427 0.81 USP2 (0.42) USP2SMN1; SMN2CTSKCYP11B2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358910-B2 Heteroaromatic compounds as Vanin inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-07-15 — — US disclosed
US-20250177362-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-06-05 — — US disclosed
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-03-04 — — US disclosed
EP-3890828-B1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2025-02-19 — — EP disclosed
CN-119343343-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 — — CN disclosed
WO-2025010311-A1 UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-01-09 — — WO disclosed
EP-4476216-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-18 — — EP disclosed
CN-114478485-B Heteroaromatic compounds as VANIN inhibitors 勃林格殷格翰国际有限公司 2024-04-05 — — CN disclosed
US-20230295112-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-09-21 — — US disclosed
US-20230295112-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-09-21 — — US disclosed
WO-2020114947-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-11 — — WO disclosed
WO-2020114949-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-11 — — WO disclosed
WO-2020114943-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-11 — — WO disclosed
US-20200172508-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-04 — — US disclosed
US-20200172508-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-04 — — US disclosed
US-20160024153-A1 STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-01-28 — — US disclosed
US-8518945-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-08-27 — — US disclosed
EP-2550273-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-01-30 — — EP disclosed
WO-2011117145-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-29 — — WO disclosed
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors SYK, ZAP70, BTK VNN1 4466/4885USP2 1770/4885SMN1; SMN2 4812/4885
US-20200172508-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS VHL, FANCI, PAH VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885
US-12240828-B2 Heteroaromatic compounds as vanin inhibitors VHL, FANCI, PAH VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885
US-12358910-B2 Heteroaromatic compounds as Vanin inhibitors VHL, FANCI, PAH VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885
US-20160024153-A1 STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF VIP, NGLY1, F13A1 VNN1 1903/4885USP2 3470/4885SMN1; SMN2 1803/4885
US-20250177362-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, IAPP VNN1 3618/4885USP2 2522/4885SMN1; SMN2 1052/4885
US-20230295112-A1 HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS VHL, FANCI, PAH VNN1 23/4885USP2 3663/4885SMN1; SMN2 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.